Neumora Therapeutics is trading up 5.24% at $0.71 on September 28, 2026; no clear company-specific reason for the gain surfaced in available search results.
- The company’s latest listed releases predate this session.
- The broader market was under pressure as oil prices and Treasury yields rose after the U.S. rejected Iran’s proposal, renewing inflation concerns; this backdrop does not directly explain the stock’s rise.